GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

PBYI · Sep 30, 2024

PUMA BIOTECHNOLOGY, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001437749-24-033955General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

98.50% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.02% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

13.70% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

43.53% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

3.32% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

63.87% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

27.41% · CORE · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

2.55% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History13 statesHistory building

Jun 30, 20230/5 normalizedLevel 3 Sep 30, 20230/7 normalizedLevel 3 Dec 31, 20230/7 normalizedLevel 3 Mar 31, 20240/6 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/8 normalizedLevel 3 Dec 31, 20240/8 normalizedLevel 3 Mar 31, 20250/8 normalizedLevel 3 Jun 30, 20255/8 normalizedLevel 3 Sep 30, 20256/8 normalizedLevel 3 Dec 31, 20256/8 normalizedLevel 3 Mar 31, 20267/8 normalizedLevel 3 Jun 30, 20268/8 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Decreased

Previous: 192.57%
Current: 98.50%
Delta: -94.07%

Cash Generation Increased

Previous: 2.18%
Current: 13.70%
Delta: 11.52%

Growth Increased

Previous: -13.72%
Current: 43.53%
Delta: 57.24%

Inventory Pressure Decreased

Previous: 19.22%
Current: 3.32%
Delta: -15.90%

Margin Decreased

Previous: 77.36%
Current: 63.87%
Delta: -13.49%

Profitability Increased

Previous: -4.63%
Current: 27.41%
Delta: 32.04%

Sbc Intensity Decreased

Previous: 4.38%
Current: 2.55%
Delta: -1.83%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · PBYI Fundamental State →Has State · PUMA BIOTECHNOLOGY, INC. →Transitioned To · PBYI Fundamental State →Transitioned To · PBYI BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · PBYI CASH_GENERATION_INCREASED →Transitioned To · PBYI GROWTH_INCREASED →Transitioned To · PBYI INVENTORY_PRESSURE_DECREASED →Transitioned To · PBYI MARGIN_DECREASED →Transitioned To · PBYI PROFITABILITY_INCREASED →Transitioned To · PBYI SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.